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Abstract An unbiased cDNA expression phage library derived from bone-marrow endothelial cells was used to
identify novel surface adhesion molecules that might participate in metastasis. Herein we report that reticulocalbin
1 (RCN1) is a cell surface-associated protein on both endothelial (EC) and prostate cancer (PCa) cell lines. RCN1 is an
H/KDEL protein with six EF-hand, calcium-binding motifs, found in the endoplasmic reticulum. Our data indicate that
RCN1 also is expressed on the cell surface of several endothelial cell lines, including human dermal microvascular
endothelial cells (HDMVECs), bone marrow endothelial cells (BMEC), and transformed human bone marrow endothelial
cells (TrHBMEC). While RCN1 protein levels were highest in lysates from HDMVEC, this difference was not statistically
significant compared BMEC and TrHBMEC. Given preferential adhesion of PCa to bone-marrow EC, these data suggest
that RCN1 is unlikely to account for the preferential metastasis of PCa to bone. In addition, there was not a statistically
significant difference in total RCN1 protein expression among the PCa cell lines. RCN1 also was expressed on the
surface of several PCa cell lines, including those of the LNCaP human PCa progression model and the highly metastatic
PC-3 cell line. Interestingly, RCN1 expression on the cell surface was upregulated by tumor necrosis factor alpha treatment
of bone-marrow endothelial cells. Taken together, we show cell surface localization of RCN1 that has not been
described previously for either PCa or BMEC and that the surface expression on BMEC is regulated by pro-inflammatory
TNF-a. J. Cell. Biochem. 104: 2298–2309, 2008.  2008 Wiley-Liss, Inc.
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The goal of this study was to identify unique
cell surface molecule(s) expressed on bone-
derived endothelial cells (BMEC) involved in
prostate cancer (PCa) metastasis by phage
display. Phage display is a powerful technique
used to identify molecules involved in cell-to-cell
and cell-to-extracellular matrix (ECM) interac-
tions, both in vitro and in vivo [Koivunen et al.,
1999]. By presenting fusion peptides on the
surface of filamentous bacteriophage, libraries
of peptides can be created and screened to
determine their roles in cell adhesion [Smith
and Scott, 1993; Koivunen et al., 1994]. Instead
of the commonly used random peptide phage
library, we used a phage cDNA expression
library derived from an established bone-
marrow endothelial cell line because it would
allow for the identification of proteins expressed
by these cells that bind to PCa cells. Through
selective and subtractive biopannings, we
identified reticulocalbin-1 (RCN1) as a potential
BMEC surface molecule. Based on the litera-
ture, RCN1 is localized to the endoplasmic
reticulum. In current study, we tested the
hypothesis that RCN1 is expressed on the
surface of endothelial and PCa cells and corre-
lates with PCa progression. The expression
of CAM on the surface of endothelial cells
is regulated by cytokines, particularly pro-
inflammatory cytokines previously shown
to function in bone [Cooper et al., 2002,
2003]. Tumor necrosis factor-alpha (TNF-a)
upregulates the surface expression of several
important CAMs, including vascular cellular
adhesion molecule (VCAM), intracellular adhe-
sion molecule (ICAM) and E-selectins. TNF-a
biosynthesis is increased in patients with
advanced PCa [Cooper et al., 2002]. Therefore,
we examined the level of RCN1 expressed on




Reagents and kits used in this study
were purchased from Invitrogen (Carlsbad,
CA) unless otherwise noted. For mRNA- enrich-
ment, cDNA synthesis, and phage display, kits
were purchased from Novagen (Madison, WI).
Cell Lines
Immortalized human dermal microvascular
endothelial cells (HDMVECs) were supplied by
Dr. Alvin Schmair University of Michigan
(Ann Arbor, MI) and maintained in defined
keratinocyte media with L-glutamine enhanced
with a growth supplement, 20% (v/v) fetal
bovine serum (FBS) and 1% (v/v) penicillin/
streptomycin (pen/strep). HBME-1 cells and
WiDr colon cancer lines (American Type Cul-
ture Collection [ATCC], Manassas, VA) were
maintained in Dulbecco’s Modified Eagle Media
(DMEM) with high glucose, GLUTAMAXTM,
110 mg/L sodium pyruvate, pyridoxine–HCl,
10% (v/v) FBS, 1% (v/v) pen/strep, and 100 ml of
plasmocin, an anti-mycoplasma agent (Invitro-
gen) [Lehr and Pienta, 1998]. BMEC were a
gift of Dr. Graca Almeida-Porada (University
of Nevada School of Medicine, Reno, NV)
[Almeida-Porada and Ascensao, 1996]. Cultures
were maintained in Medium 199 with Earles’s
salts, L-glutamine, 2,200 mg/L sodium bicar-
bonate, 25 mM HEPES buffer, 10% FBS,
1% pen/strep, endothelial cell growth supple-
ment (BD Biosciences, Bedford, MA), and
7,500 u/500 ml media of heparin (Sigma, St.
Louis, MO). The TrHBMEC were maintained as
previously described [Schweitzer et al., 1997] in
DMEM media, with 5% FBS and 10 mM HEPES
buffer. Most importantly, at some time, the
HBME cell line became contaminated with
canine cells that were being grown concurrently
in the laboratory. Because we could not ascer-
tain with confidence when this occurred, all
subsequent and reported experiments were
performed with the BMEC and TrHBMEC
cell lines that were clearly demonstrated to be
of human origin by DNA sequence analysis
of RCN1 RT-PCR products. LNCaP, C4-2, and
C4-2B4 sublines from the LNCaP progression
model of PCa [Thalmann et al., 2000] were
maintained in T media with 5% (v/v) FBS
without antibiotics. The PC-3 (PCa cell line)
and WiDr (colon cancer cell line) cell lines
were obtained from ATCC. The PC-3 cell line
was maintained in Ham’s F-12 medium with
2 mM L-glutamine, 1,500 mg sodium bicarbonate,
10% (v/v) FBS and 1% (v/v) pen/strep. All cell
lines were maintained at 378C in a 5% CO2
incubator.
RNA Isolation and cDNA Synthesis
Briefly, total RNA was isolated from confluent
cells by the Trizol method and quantitated
using Smart Spec 3000 (Bio-Rad, Hercules,
CA). For use in the T7 select phage display
system, total RNA was enriched for mRNA
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transcripts using the Straight A’s mRNA Iso-
lation System. The mRNA transcripts were
transcribed into cDNAs using the Novagen
directional synthesis kit and oligo dT primers.
For ratiometric RT-PCR and quantitative
RT-PCR, cDNAs, 4 mg of total RNA were used
for the iScriptTM cDNA synthesis kit with oligo
dT primers.
Construction and Biopanning of a Bone-Marrow
Derived Endothelial Phage Expression Library
The protocols for phage display and biopann-
ing are illustrated in Figure 1. Bone-marrow
endothelial cell derived cDNAs were inserted by
directional cloning into a T7Select10-3b vector.
Phage display was performed as described in
the manufacturer instructions with modifica-
tions. The bone-marrow endothelial phage
library was biopanned on both WiDr cells,
a non-metastatic colon cancer cell line, and on
PC-3 cells, a PCa cell line derived from a bone
metastasis. Subtractive biopanning on WiDr
cell monolayers was performed to eliminate
phage particles with non-specific binding acti-
vity. WiDr cells were grown to confluence in
96-well plates. The media was removed and
the monolayers were incubated for 20 min at
48C in blocking buffer (phosphate-buffered
saline (PBS) with 1% (w/v) bovine serum
albumin (BSA)). Approximately 109 plaque-
forming units of the BME phage expression
library were added to the blocking solution and
incubated over the WiDr monolayers for 1 h at
48C. The monolayers were washed five times
and the supernatants were pooled after each
wash. The supernatant, which contained
phage particles that were not able to bind to
WiDr monolayers, was then applied to PC-3 cell
monolayers. PC-3 cell monolayers were incu-
bated in blocking buffer for 20 min at 48C and
then the pooled supernatant from the WiDr
monolayers was applied and allowed to incubate
for 1 h. After five washes with wash buffer (PBS
with 0.1% (v/v) Tween 20), the attached phage
were eluted with T7 elution buffer for 20 min,
then amplified by infecting 25 ml of log phase
BLT5403 bacterial cells. The resulting phage
titer was determined by the plaque assays
described in the T7 Select system manual
and biopanning was repeated twice on PC-3
monolayers. Following the last biopanning, the
attached phage were eluted and amplified in
BLT5403 bacterial cells. Plaque assays were
performed and random colonies were eluted
in phage extraction buffer (20 mM Tris–HCl,
pH 8.0, 100 mM NaCl, 6 mM MgSO4) overnight
Fig. 1. Construction of the HBME Phage display library. Total
RNA was isolated from HBME cells, reverse transcribed to
cDNA, digested and packaged in a T7 Select10-3b phage vector.
The HBME T7 phage expression vectors were grown in BLT5403
bacteria and a subtractive biopanning was performed on
monolayers of WiDr cells. The non-adherent phage were
collected and used for three rounds of conventional biopanning
on monolayers of PC-3 cells. This step was enriched for phage
expressing cDNA that preferentially bound to PC-3 cells. After
several washes, phage attached to PC-3 cells were eluted, PCR
amplified and sequenced as detailed in the materials and
methods section.
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at 48C. Insert sizes were determined by PCR
using T7 forward and reverse primers and
nucleotide sequences were determined at the
University of Michigan’s DNA Sequencing Core
Facility.
RT-PCR and Sequence
RT-PCR for RCN1 expression was performed
using specific primers (forward 50-GAGGA-
CAACCAGAGCTTCCA-30 and reverse 50-TCT-
GCCAGTTCAGTCCACAG-30) (MWG Biotech,
Greensboro, NC) to generate a 1750 bp product.
As a loading control, b-actin primers (forward
50-GCTCG TCGTCGACAACCGGCTC-30 and
reverse 50-CAAACATGATCTGGGTCATCTTC-
TC-30) were used to generate a 353 bp product.
Each RT-PCR reaction utilized 4 mg of total
RNA. RCN1 was amplified by PCR using 10%
(corresponding to 0.4 mg total RNA) of the cDNA
reaction for each cell line using the Super-
ScriptTM III First Strand RT-PCR kit using a
Platinum Taq DNA polymerase and 30 cycles.
PCR products were separated on a 0.8% TBE
agarose gel and visualized with ethidium
bromide. RT-PCR was performed on all endo-
thelial cell (EC) lines, all of the cell lines of
the LNCaP progression model, PC-3 cells and
cDNAs from the following human organs: bone
marrow, brain (cerebellum), kidney, and pros-
tate (BD Biosciences, Bedford, MA).
Specificity of selected primers used for RT-
PCR amplification of RCN1 was confirmed by
direct DNA sequencing. Four PCR reactions
were performed utilizing the aforementioned
protocol on each of the cell lines in the LNCaP
progression model. The PCR-products were gel
purified using low melt agarose (Bio-Rad) and
QIAquick Gel Extraction kit (Qiagen, Valencia,
CA). Sequencing was performed in both direc-
tions using the ABI BigDye Terminator Cycle
sequencing Ready Reaction kit v3.1 using a one-
fourth dilution of the terminator mix, and
analyzed on an ABI3130XL Genetic Analyzer.
Sequences generated during this study were
assembled and analyzed using MacVector7.1.1
(Accelrys, San Diego, CA) and the BLAST
program [Altschul et al., 1990] available on the
National Center for Biotechnology Information
(NCBI) web site. Secretome P 2.0 was used
to predict the secretion of RCN1 http://
www.cbs.dtu.dk/services/secretomep/. A value
greater than 0.5 strongly suggest that a protein
is secreted [Bendtsen et al., 2004]. Also,
the presence of transcription factor binding
sites in the RCN1 promoter was deter-
mined using MatInspector/TRANSFAC from




To compare RCN1 transcript levels in the
cell lines, quantitative real-time Q-PCR was
performed. Approximately, 1 106 cells were
trypsinized and rinsed in PBS. Cells then were
lysed and total RNA was isolated by centri-
fugation through spin columns using the SV
Total RNA Isolation System (Promega). cDNA
was generated (4 mg total cellular RNA per
reaction) by reverse transcription using Oligo
(dT) 15 primer (Promega) and SuperScript III
(500 units per reaction; Invitrogen) for first
strand synthesis and Tfl DNA polymerase
for second strand synthesis (500 units per
reaction; Promega) as per the manufacturer’s
protocol. Typically, 20 pg of each cDNA was used
for each PCR reaction. Two-step Q-PCR was
performed on cDNA generated using the Multi-
Scribe reverse transcriptase from the TaqMan
reverse transcription system and the SYBR
Green PCR Master Mix (PE Biosystems). The
primer pairs for RCN1 were generated from the
published sequences (forward 50-TGCAGACCT-
CAATGGTGACCT-30 and reverse 50-AAGG-
CAGTGAACTCCTCCCG-30). Reactions were
performed in MicroAmp Optical 96-well Reac-
tion Plate (PE Biosystems). Forty cycles of PCR
were performed under standard conditions
using an annealing temperature of 608C. The
cycle threshold (Ct) was determined by the cycle
number at which exponential amplification
began. The Cts were averaged from the values
obtained from the triplicate repeats used to
calculate delta Ct normalized to b-actin for
endothelial cells and GAPDH in PCa cells using
TrHBMEC (TR) as endothelial controls and
LNCaP as controls for PCa cells. All reactions
were carried out in triplicate.
Western Blotting
Proteins from cell lysates were obtained from
confluent monolayers that had been washed
3 times with PBS before lysing in 20 mM Tris
(pH 8) containing 137 mM NaCl, 1% (v/v) NP40,
10% (v/v) glycerol, 1 mM Na3VO4, 1.7 mg/ml
aprotinin, 50 ml/ml leupeptin, and 1 mM PMSF.
Lysed cells were detached by scraping and
the mixture was centrifuged at 13,200 rpm for
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10 min. Membrane proteins were obtained from
confluent monolayers as described previously
[Cooper et al., 2002]. The supernatant was
collected and stored at 808C. Protein concen-
trations were determined by a Bradford assay
(Bio-Rad).
To determine protein expression of RCN1,
50 mg of protein from the soluble fractions were
resolved in 10% (w/v) SDS-polyacrylamide gels
on a Minigel apparatus (Bio-Rad) and trans-
ferred to a PVDF membrane (ImmobilonTM-P,
Millipore) using a semidry transfer (Bio-Rad).
The membrane was blocked for 1 h with 3% (w/v)
BSA in TBS (273.8 mM NaCl, 5.4 mM KCl,
and 38.1 mM Tris) with 1% (v/v) Tween 20, the
membrane was incubated with the primary
antibody at the appropriate dilution, rabbit
anti-reticulocalbin 1:3,000 (prepared commer-
cially by Bethyl Laboratories, Montgomery TX
and targets the EF-hand domain of the protein),
rabbit anti-actin 1:5000 (Sigma), and rabbit
anti-b1-integrin 1:2,000 (Santa Cruz, Santa
Cruz, CA), in 3% (w/v) BSA in TBS. Anti-b1-
integrin was used as a loading control for
membrane preparation. Anti-primary antibody
exposure was carried out at 48C for 18 hr and
membranes then washed 3 times with TBS-T
(273.8 mM NaCl, 5.4 mM KCl, 38.1 mM Tris,
and 0.1% (v/v) Tween 20). For RCN1 detection,
the membrane then was probed with goat anti-
rabbit IgG HRP-linked 1:10,000 (Cell Signaling,
Danvers, MA) for 1 h at room temperature
and washed four times with TBS-T. For b-actin
and b1-integrin immunodetection, the mem-
branes were probed with goat anti-rabbit
IgG HRP-linked 1:20,000 (Cell Signaling), incu-
bated for 1 hr at room temperature, and washed
four times with TBST. The immunoblots
were visualized by chemiluminescence with
LumiGlo1 (Cell Signaling). Membranes were
treated with stripping buffer (100 mM
b-mercaptoethanol, 2% (w/v) SDS, 62.5 mM
Tris–HCl) for 45 min at 708C, washed
twice with TBST for 15 min, then were re-
blocked and probed. All Westerns were done
three times.
Flow Cytometry
Flow cytometric analyses were performed as
described previously [Cooper et al., 2000, 2002].
Selected cell lines were seeded in T75 flasks and
grown to confluence. For TNF-a treatment,
BMEC and PCa cells were allowed to reach at
least 80% confluency and then exposed to 400 U
of TNF-a for 4 and 24 h. Cell monolayers were
detached from plastic substrata with dis-
adhesion medium (0.5 mM EDTA, 10 mM
glucose, 1 PBS) and approximately 2.5–
5 105 cells were analyzed per run. After
staining, cells were analyzed for fluorescence
using a BD Bioscience FACSCalibur. The
percentage of RCN-1 positive cells was deter-
mined using Cell Quest from Acquisition/
Analysis software (BD Bioscience). This experi-
ment was done four times.
Confocal Immunofluorescence Microscopy
HBME-1, TrHBMEC and BMEC cells
were grown on #1.5 18 mm coverslips to sub-
confluency prior to fixation with either 4% (v/v)
paraformaldehyde in 0.1 M PBS pH 7.2 or
cold methanol (208C) for 45 min. For RCN1
endoplasmic reticulum (ER) labeling, parafor-
maldehyde-fixed cells were permeabilized with
0.1% (v/v) Triton X-100 (Sigma, St. Louis, MO)
for 10 min prior to immunolabeling. RCN1 and
b1-integrin detection at the plasma membranes
were obtained after cold methanol or parafor-
maldehyde fixation, respectively, omitting Tri-
ton-X treatment. All samples were blocked in
3% (w/v) BSA (Sigma) and 10% (v/v) normal goat
serum in PBS, pH 7.2 for 1 h. Affinity-purified
rabbit anti-RCN1 was used at a dilution of 1:500
in blocking buffer followed by Alexa Fluor
555 goat anti-rabbit IgG (A-21429, Invitrogen,
Eugene, OR) at a dilution of 1:500 in blocking
buffer with DRAQ-5 (Invitrogen) at 1:1,000 to
visualize nuclei (in some experiments). Mouse
monoclonal IgG1 anti-b1-integrin (Santa Cruz)
was used at a dilution of 1:100 followed by Alexa
Fluor 488 goat anti-mouse IgG1 (Invitrogen) at
a dilution of 1:500. All coverslips were mounted
in Biomeda Gel/Mount (Electron Microscopy
Sciences, PA) and sealed with nailpolish. Con-
trols included the omission of primary anti-
body, secondary antibody, and/or peptide block
(anti-RCN1 primary antibody incubated over-
night in blocking peptide—1 ml antibody to 5 ml
peptide). Confocal images were acquired on a
Zeiss Axiovert 200M equipped with a LSM 510
NLO laser-scanning microscope (Carl Zeiss,
Inc., Germany) using a Zeiss 40X Plan-Neofluar
objective lens (NA 1.3). Images of Alexa Fluor
488, Alexa Fluor 555 and/or DRAQ-5 staining
were acquired using the 488 nm laser line of a
25 mW Argon laser (LASOS, Germany) and
543 and 633 nm Helium Neon lasers (LASOS)
with the 500–550 nm band pass, 560–610 nm
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band pass and 650 nm long pass emission filters,
respectively.
Statistical Analysis
Q-PCR results were statistically analyzed
using the Student’s t-test for unpaired values.
P values were determined by a two-sided
calculation, and a P value of less than 0.05 was
considered statistically significant. Statistical
differences are indicated by asterisks. Flow
cytometry was analyzed using a paired Student
t-test to determine statistical significance. A
P value of less than 0.05 was considered
significant.
RESULTS
RCN1 is Expressed in Established
Endothelial Cell Lines
In this study, a phage display expressed
cDNA insert derived from a bone-marrow
endothelial cell line was employed to identify
proteins potentially involved in PCa cell adhe-
sion. Several phage were identified containing
cDNAs that adhered specifically to PC-3 cell
monolayers. To enrich phage library for specific
binding to PC-3, a subtractive biopanning on
WiDr cells, which adhere poorly to HBME-1 cell
monolayers, was done [2]. Using this approach,
we identified a DNA sequence encoding a highly
conserved calcium-binding domain correspond-
ing to the EF-hand calcium-binding domain of
human RCN1 (accession number BC010120)
(data not shown).
To profile the expression of RCN1 in well
characterized endothelial cell lines, Q-PCR
analyses were performed using total RNA
extracted from two independently derived
bone-marrow endothelial cell lines, BMEC,
and TrHBMEC, and one dermal microvascular
endothelial cell line, HDMVEC (Fig. 2). Charac-
terization of cell surface expression of VCAM
and ICAM (data not shown) following TNF-a
treatment, indicated that TrHBMEC and
BMEC are more similar to primary human
bone-marrow endothelium than are HBME-1;
as such, they were used for all subsequent
experiments [Almeida-Porada and Ascensao,
1996; Schweitzer et al., 1997; Lehr and Pienta,
1998; Cooper et al., 2002]. The data generated
from Q-PCR showed that RCN1 mRNA was
preferentially expressed in HDMVEC com-
pared to bone-marrow endothelial cell lines
(Fig. 2). The expression of RCN1 transcript
was 10 fold higher in the HDMVEC cell line
compared to BMEC and TrHBMEC. BMEC
expressed more RCN1 transcript compared to
TrHBMEC.
To determine if RCN1 mRNA expression
corresponded to RCN1 protein levels in these
cell lines, Western blot analyses were performed
using cell lysates and membrane preparations
(Fig. 3). As with mRNA expression, RCN1
protein levels were highest in the HDMVEC cell
lysate compared to bone-marrow endothelial
cell lysates. Unlike RNA expression, BMEC
expressed less RCN1 protein compared to
TrHBMEC. Two bands were detected and were
uniformly expressed in all endothelial cell lines.
Interestingly, evaluation of membrane fractions
derived from these endothelial cell lines demon-
strated that HDMVEC expressed a high level
of RCN1 compared to BMEC and TrHBMEC.
Fig. 2. The detection of RCN1 transcript expression in
endothelial cell lines. b-Actin was used as a loading control.
Q-PCR analysis of RCN1 expression in endothelial cell
lines based on delta Cts (TR¼ TrHBMEC, BMEC, and HD¼
HDMVEC).
Fig. 3. Western analysis of RCN1 protein expression in
endothelial cell lines. A: RCN1 in endothelial cell lysates
(HDMVEC, TrHBMEC, and BMEC). B: RCN1 in endothelial cell
membrane fractions. Fifty micrograms of proteins was resolved
for both cell lysate and membrane fractions.
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RCN1 expression between the two bone-marrow
EC were similar. Although two bands are
detected and both are RCN1, the lower band
was prevalent in the bone-marrow endothelial
cell lines while the upper band was prevalent in
HDMVEC. According to the manufacturer, both
bands are RCN1 based on mass spectrometry.
Actin was used as a loading control for cell
lysates and b1-integrin was used as a loading
control for crude membrane preparations.
These data demonstrated that RCN1 expression,
although isolated by phage display from a bone-
marrow endothelial cell line, is not unique to
this cell type and may not contribute preferen-
tially to PCa cells adhering to bone-marrow
endothelium.
RCN1 is Expressed in Established PCa Cell Lines
RCN1 mRNA expression was assessed in
established PCa cell lines by Q-PCR (Fig. 4).
Here demonstrated a two-fold increase in RCN1
(Fig. 4A) associated with the progression
from androgen sensitive (LNCaP) to androgen
insensitive (C4-2). However, when comparing
cells that are bone adapted, such as C4-2 versus
C4-2B4 and PC-3, RCN1 mRNA expression
was reduced by 60% and 50%, respectively.
Although the difference in RCN1 protein
expression level was not statistically significant
based on denisometric analysis (data not
shown), there was a trend for increased RCN1
expression in osteoblastic C4-2B4 compared to
osteolytic PC-3 cells (Fig. 4B). Finally, the level
of protein expression did not correlate with the
mRNA expression profile (Fig. 4B).
Pooled cDNAs derived from normal bone-
marrow, brain, kidney and prostate tissues
were examined for RCN1 expression using RT-
PCR (Fig. 5) to determine if RCN1 mRNA
expression correlated with the metastatic
pattern of PCa: bone> brain>kidney(rare).
Only brain has noticeably higher RCN1 mRNA
levels, while bone marrow actually appears to
have a much lower level of RCN1 mRNA
compared to the other tissues. These observa-
tions indicate that RCN1 transcript expression
is common in normal tissues and the levels do
not correlate with the metastatic pattern of
PCa.
RCN1 Is an ER Lumen Protein That Is
Expressed at the Cell Surface
RCN1 is a protein reported to reside in the ER
lumen and has a classic ER retention signal
(KDEL). Calreticulin also is found predomi-
nantly in the ER lumen, but also has been
shown to be expressed in other sub-cellular
compartments, including the plasma mem-
brane where it participates in cell adhesion
[Opas et al., 1996; Goicoechea et al., 2000;
Johnson et al., 2001]. Based on published
information regarding calreticulin, we eva-
luated our cell lines for the surface expression
of RCN1. Despite the presence of an ER
retention signal, we found RCN1 protein in
membrane fractions of bone-marrow EC, indi-
cating that RCN1 also could be associated with
the plasma membrane. Flow cytometry on live
EC and PCa cell lines confirmed that RCN1 was
expressed on the surface of all EC lines tested
(Table I). We found the highest surface expres-
sion on BMEC followed by HDMVEC and then
TrHBMEC. In addition, we found significant
surface expression of RCN1 on LNCaP and
C4-2B4 cells, but lower levels in PC-3 cells.
Fig. 4. Detection of RCN1 expression in PCa cell lines. A: Q-PCR
analysis of RCN1 transcript expression in PCa cell lines based on
average delta Cts. B: RCN1 protein expression in PCa cell lysates
(PC-3, LNCaP, C4-2, and C4-2B4) as determined by Western
analysis of 50 mg of proteins resolved on a SDS gel.
Fig. 5. The RCN1 transcript expression in normal human tissues
(BM¼bone marrow, Br¼brain (cerebellum), K¼ kidney, and
Pr¼ prostate) as determined by conventional RT-PCR at
30 cycles.
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Compilation of the FACS and Western data
strongly suggest that RCN1 is expressed on the
cell surface.
To validate the surface expression of RCN1,
we used confocal microscopy to examine the sub-
cellular distribution of RCN1 in bone-marrow
ECs (Fig. 6). Figure 6A shows tubular staining
indicating that RCN1 was prevalent in the ER of
bone-marrow endothelial cell line HBME-1. We
then demonstrated the presence of RCN1 on
the plasma membrane of HBME-1 cells using
methanol fixation (Fig. 6C). Treatment of Triton
X-100-treated and untreated HBME cells
with peptide block prevented the RCN1 anti-
body from specifically binding to both ER
RCN1 (Fig. 6B) and plasma membrane RCN1
(Fig. 6D), validating the specificity of RCN1
antibody. We also showed surface expression of
RCN1 in TrHBMEC (Fig. 6G) and BMEC
(Fig. 6H) cell lines to confirm it presence in
human bone-marrow endothelia cells. To verify
surface localization of RCN1, we examined cell
surface expression of the b1-integrin subunit
that is known to be restricted to the cell
surface [Cooper et al., 2000, 2002] in TrHBMEC
(Fig. 6E) and BMEC (Fig. 6F) cells. Interest-
ingly, RCN1 staining is enriched at the cell-to-
cell junctions in both BMEC and TrHBMEC,
similar to b1-integrin. These observations sug-
gest the RCN1, is expressed both in the lumen of
the ER and the surface of the plasma membrane
in bone-marrow EC. This is the first report
demonstrating surface expression of RCN1
on ECs, including those derived from bone-
marrow, as well as PCa cells.
After demonstrating that RCN is expressed
on the surface of bone-marrow endothelial cells,
we evaluated the ability of TNF-a to upregulate
the surface expression of RCN1 on BMEC
endothelial cells (Fig. 7). Sequence analysis
demonstrated that the promoter of RCN1 con-
tains a binding site for transcription factors
(AP-1) regulated by pro-inflammatory cyto-
kines. TNF-a was selected because its levels
are upregulated in men with advanced PCa
[Cooper et al., 2002; Nabors et al., 2003]. The
data demonstrated that 4–24 h TNF-a treat-
ment of BMEC produced a threefold increased
in RCN1 surface expression, that approached
statistical significant (the p value is 0.065 for
the 4 h and 0.079 for the 24 h treatment). PCa
cells with varied metastatic potential for bone
were evaluated also for chronic (24 hrs) expo-
sure to TNF-a (Table II). Although there was a
trend for TNF-a to increase RCN1 surface
expression on cells with high metastatic poten-
tial, PC-3 and C4-2B4, the increase was not
statistically significance and not as dramatic as
RCN1 surface expression observed on BMEC
during acute (4 h) and chronic (24 h) TNF-a
stimulation. Thus, under pro-inflammatory
conditions found in bone metastasis, RCN is
highly expressed on bone-marrow endothelial
cell surfaces (Table II).
DISCUSSION
PCa cell adhesion to microvascular endothe-
lium is a necessary step in the cascade of events
leading to metastasis [Lehr and Pienta, 1998;
Cooper et al., 2000; Scott et al., 2001]. Although
several integrins and lectins have been impli-
cated in this process [Kierszenbaum et al., 2000;
Scott et al., 2001], the specific cell adhesion
molecules (CAMs) expressed on bone endothe-
lium necessary for the adhesion of PCa cells
remain unknown. Scott and colleagues [Scott
et al., 2001] demonstrated that b1-integrins
were involved in PC-3 cell adhesion to bone-
marrow endothelial cells (EC). In contrast, we
have found that b1-integrins expressed on
receiving BME-1 cells were not involved in
adhesion to bone-marrow endothelial cells
[Cooper et al., 2000]. Kierszenbaum et al.
[2000] showed that the galactosyl receptor, a
cell surface C-type lectin, mediated PCa cell
adhesion to BME-1 cells. These investigations
indicate that several conventional cell surface
molecules are involved in PCa-HBME interac-
tion; however, other unique surface molecules
also may be involved.
Bacteriophage display systems have been
extensively used to isolate cell surface mole-
cules [Koivunen et al., 1994; Koivunen et al.,
1999; Romanov and Goligorsky, 1999]. Using
phage display, we have identified a portion of
RCN1 as a cell-surface interacting protein with
TABLE I. Relative Surface Expression of
RCN1 on Endothelial and PCa Cell Lines
Determined by FACS
Cell lines
Average percentage of cells positive
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bone adapted PC-3 cells in vitro. Ozawa and
Muramatsu [1993] first described human RCN1
as a protein with six Ca2þ-binding domains
[Tachikui et al., 1997] that is located in the
lumen of the ER [Ozawa and Muramatsu, 1993].
The function of RCN1 is not known, but it
has been speculated to play a role in Ca2þ
dependent cell adhesion [Nimmrich et al.,
2000]. Strong expression of RCN1 correlates
with a low expression of Ca2þ-dependent cad-
herin, a metastatic predictor, in both breast
cancer and colorectal cancer cells [Liu et al.,
1997; Nimmrich et al., 2000]. A recent study
reported that RCN1 is down-regulated in
Fig. 6. Confocal microscopy examination of RCN1 in the ER
and on the cell surface in three bone-marrow endothelial
cell lines. A: RCN1 in the ER of HBME-1. B: RCN1 peptide
block. C: RCN1 on the surface of non-HBME-1 (arrows).
D: RCN1 peptide block. E: b1-integrin subunit staining in
TrHBMEC. F: b1-integrin subunit staining on BMEC. G: RCN1
staining on the cell surface of TrHBMEC. H: RCN1 staining on the
cell surface of BMEC. The arrows indicate RCN1 surface location
and cell-to-cell location. Scale Bars for A–D¼ 50 mm and for
E–H¼ 20 mm.
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cisplatin-resistant non-small cell lung cancer
tissue samples [Hirano et al., 2005]. Trans-
fection of RCN1 into these cisplatin resistant
cell lines restored sensitivity to cisplatin, sug-
gesting that RCN1 enhances sensitivity of lung
cancer cells to cisplatin. Although these studies
provide insight into possible functions of RCN1,
the exact function of RCN1 in normal and
cancerous cells still is not known.
Herein we report for the first time that (1)
RCN1 is expressed in EC lines, including bone-
marrow ECs, (2) is expressed on the surfaces of
EC cells and (3) is expressed on the surface of
PCa cell lines. The surface expression was
validated by flow cytometry and confocal micro-
scopy. Interestingly, by FACS, we observed the
BMEC expressed more surface RCN1 compared
to TrHBMEC and HDMVEC. This is appears to
contradict data generated from Western analy-
sis of membrane preparation. One reason for
this outcome is that the membrane preparation
is crude and would contain Golgi and ER
membranes, where as with FACS, only protein
expression at the surface of the plasma mem-
brane is being examined. Also, Western blot
evaluation of membrane preparation reveal
that the lower band is prevalent in the bone-
marrow-derived EC compared to HDMVEC.
This lower band may be the result of additional
post-transational modification and locate pre-
dominately at the cell surfaces. While RCN1
has a KDEL sequence, which targets it to the
lumen of the ER, several studies have reported
the distribution of several KDEL containing
proteins, including protein disulfide isomerase,
a 78-kDa glucose-regulated protein (GRP78),
and calreticulin, to the plasma membrane [Xiao
et al., 1999; Johnson et al., 2001; Nabors et al.,
2003]. Specifically, calreticulin, is expressed on
the surface of bovine aortic ECs and interacts
with thrombospondin to mediate focal adhesion
disassembly [Goicoechea et al., 2000]. Like
calreticulin, RCN1 at the plasma membrane
may participate in cell adhesive events, as
shown by its location at cell-to-cell junction in
endothelial cells. However, because of the level
of RCN1 protein expression in HDMVEC, it is
unlikely that RCN1 is the candidate molecule
responsible for preferential adhesion of PCa to
bone endothelium.
Also, we are the first to demonstrate RCN1
expression in a PCa progression model system.
RCN1 is over expressed in an invasive breast
cancer cell line, MDA-MB-435, and in an
invasive colorectal cancer cell line, SW480
[Liu et al., 1997; Nimmrich et al., 2000]. These
observations imply that RCN1 expression cor-
related with cancer progression; however, these
studies examined RNA expression and used a
non-linear cell models for cancer progression.
Using the lineage related PCa sublines of the
human LNCaP PCa progression model system,
we found very similar levels of RCN1 proteins
among PCa cell lines even though there were
differences in steady state mRNA levels. For
example, mRNA expression was lower in more
aggressive, bone adapted PCa cell lines (PC-3
and C4-2B4) than in those that were derived
from the bone-marrow metastases compared to
RCN1 mRNA expression in LNCaP and C4-2.
However, the protein expression of RCN1
was approximately similar between LNCaP,
C4-2 and C4-2B4 cells. Using flow cytometry, we
demonstrated that RCN1 was expressed on the
cell surface in a subpopulation of PCa cells. Its
Fig. 7. FACS analysis of RCN1 surface expression on TNF-a
treated BMECs. BMEC were treated for 4 and 24 h with 400 U of
TNF-a. Control is untreated BMEC for 24 h.
TABLE II. The Surface Expression of RCN1 on PCa Cells With Varying Metastatic Potential
During Chronic (24 h) TNF-a Exposure*
LNCaP LNCaP-TNFa C4-2 C4-2TNFa C4-2B4 C4-2B4-TNFa PC3 PC3-TNFa
100 11 1148 100 32 110 24 100 83 15683 10070 182 64
*Data are presented at fold change relative to untreated control for each cell line.
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expression was the highest in LNCaP and
C4-2B4 and lowest in PC3, suggesting that its
surface expression does not correlate with PCa
progression to the bone.
Inflammation is a common complication in
cancer patients and upregulates surface expres-
sion of several CAMs on proximal microvascular
endothelial [Fayth et al., 2007]. In the current
study, we showed that the surface expression of
RCN1 on bone-marrow EC and bone-marrow-
derived PCa cells was increased in the presence
of TNF-a, a pro-inflammatory cytokine that is
often over-expressed in men with advanced
metastatic PCa [Cooper et al., 2002]. This
observation suggests that the expression of
RCN1 on the endothelial cell and metastatic
PCa surfaces is increased under the pro-
inflammatory condition often found in bone
metastasis and may contribute to metastatic
progression in this tissue. An antibody to RCN1
failed to block the adhesion of PC-3 to BMEC,
suggesting that RCN1 may not be a mediator
of PCa-BMEC adhesion (data not shown).
However, it should be noted that the antibody
used was against the EF-hand region of the
protein and has not been reported to have
blocking function.
In conclusion, while mRNA levels encoding
RCN1 are not useful markers for PCa progres-
sion or for identification of surface receptive
endothelial cell populations, cell surface levels
of RCN1 may serve as useful indicators of pro-
adhesive endothelial cells. Additional studies
are underway to determine the functional
significance of cell surface RCN1 and its
presentation at the cell surface by inflammatory
mediators associated with PCa metastasis to
bone.
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